?????????????????????? ???????????????FDA’s budgetary dependence on user costs may possibly advantage marketplace in negotiating favorable policy alterations as a result of PDUFA.Negotiations about the 2022 reauthorization advise that marketplace priorities incorporate improved application of authentic-world evidence, regulatory certainty, and gr